This primary end point was achieved by 48 of 118 patients ( 40.7 % ) in the placebo group , and by 51 of 128 ( 39.8 % ) and 52 of 122 ( 42.6 % ) in the pentosan polysulfate sodium 100 mg once daily and 3 times daily groups , respectively .